The abstract is read at the publisher; the summary is JClub's.
Re-analysis of prevalence data in people with type 2 diabetes suggests advanced fibrosis in MASLD may be below 5–10%, challenging earlier 20–40% estimates that drove screening.
- Why it matters: Progression to end-stage liver disease is uncommon, so clinicians need to identify a small high-risk subset, but current screening recommendations may be based on overestimated AF burden.
- What they did: This review evaluates evidence for MASLD-related AF screening and diagnosis, including re-analysis of prevalence studies plus simulations and emerging real-world data on referral rates and test accuracy.
- The result: Non-invasive tests may refer 30–50% for second-line testing and 15% for specialist evaluation, with high false positives and missing more than a third of AF cases, while management/outcome benefit remains uncertain.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.